Can MammaPrint guide treatment decisions?
Full article:

The American Society of Clinical Oncology (ASCO) updated its guidelines for MammaPrint, a genomic tumor test that guides treatment decisions for patients with early-stage invasive breast cancer. The update was based on results from the MINDACT study (11/16/17). 

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following are studies enrolling people with early stage ER-positive, HER2-negative breast cancer. 

A number of other clinical trials for patients with early-stage breast cancer can be found here.


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.